Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First in Human Study of Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis

Trial Profile

First in Human Study of Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Pulmonary alveolar proteinosis
  • Focus Adverse reactions; First in man
  • Acronyms PioPAP
  • Most Recent Events

    • 31 Jan 2019 Planned End Date changed from 1 Jul 2018 to 1 Jun 2020.
    • 31 Jan 2019 Planned primary completion date changed from 1 Jul 2018 to 1 Jun 2019.
    • 31 Jan 2019 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top